Key Takeaways
- • Esperion Therapeutics agreed to be acquired by healthcare investment firm Archimed in a $1.1 billion take-private transaction, ending its tenure as a public company.
- • Goodwin Procter LLP served as legal counsel to Esperion, while Sidley Austin LLP advised the acquiring firm Archimed on the transaction.
- • The deal represents a significant consolidation move in the biopharmaceutical sector, with Archimed positioning itself as an active acquirer in healthcare-focused investments.
- • The transaction was announced on Friday, May 1, 2026, marking a definitive exit for Esperion's public shareholders.
Summary
Biopharmaceutical company Esperion Therapeutics announced on Friday, May 1, 2026, that it has agreed to be acquired by Archimed, a healthcare-focused investment firm, in an all-cash take-private transaction valued at $1.1 billion. The deal represents a strategic consolidation within the biopharmaceutical sector and marks Esperion's transition from public markets to private ownership under Archimed's portfolio.
Goodwin Procter LLP served as legal counsel to Esperion Therapeutics throughout the transaction process, while Sidley Austin LLP advised Archimed on the acquisition. The involvement of both prominent law firms underscores the complexity and scale of the transaction, with each advisor managing distinct regulatory and strategic considerations for their respective clients.
Archimed's acquisition of Esperion reflects the investment firm's focus on identifying and acquiring companies within the healthcare space. The $1.1 billion valuation represents the firm's assessment of Esperion's strategic value and growth potential within its private investment portfolio. The take-private structure enables Archimed to manage Esperion's operations outside the constraints and reporting requirements of public markets, potentially allowing for longer-term strategic initiatives and operational restructuring.
The transaction closed on Friday, May 1, 2026, completing the transition of Esperion from public company status to private ownership.
Goodwin Procter LLP served as legal counsel to Esperion Therapeutics throughout the transaction process, while Sidley Austin LLP advised Archimed on the acquisition. The involvement of both prominent law firms underscores the complexity and scale of the transaction, with each advisor managing distinct regulatory and strategic considerations for their respective clients.
Archimed's acquisition of Esperion reflects the investment firm's focus on identifying and acquiring companies within the healthcare space. The $1.1 billion valuation represents the firm's assessment of Esperion's strategic value and growth potential within its private investment portfolio. The take-private structure enables Archimed to manage Esperion's operations outside the constraints and reporting requirements of public markets, potentially allowing for longer-term strategic initiatives and operational restructuring.
The transaction closed on Friday, May 1, 2026, completing the transition of Esperion from public company status to private ownership.
Go deeper than the headline
Research every firm in this story, track the ones that matter and get the daily briefing — free for 7 days.